US7816492B2
(en)
|
1998-11-20 |
2010-10-19 |
Arena Pharmaceuticals, Inc. |
Human G protein-coupled receptors
|
USRE42190E1
(en)
|
1998-11-20 |
2011-03-01 |
Arena Pharmaceuticals, Inc. |
Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
|
US20030017528A1
(en)
|
1998-11-20 |
2003-01-23 |
Ruoping Chen |
Human orphan G protein-coupled receptors
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
AU2002213925A1
(en)
|
2000-09-18 |
2002-03-26 |
Osteometer Biotech As |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
SE0004054D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
JP2004526756A
(ja)
*
|
2001-04-06 |
2004-09-02 |
スミスクライン ビーチャム コーポレーション |
hYAK1及びhYAK3キナーゼのキノリン阻害剤
|
AU2002253361B2
(en)
|
2001-05-05 |
2006-08-17 |
Smithkline Beecham P.L.C. |
N-aroyl cyclic amines
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
NZ532427A
(en)
|
2001-09-24 |
2008-07-31 |
Imp Innovations Ltd |
Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
|
EP1444219A1
(fr)
|
2001-10-12 |
2004-08-11 |
Novo Nordisk A/S |
Piperidines substituees et leur utilisation dans le traitement de maladies liees au recepteur histaminique h3
|
KR101018318B1
(ko)
|
2001-12-21 |
2011-03-04 |
노보 노르디스크 에이/에스 |
Gk 활성제로서의 아미드 유도체
|
CA2472882A1
(fr)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Utilisation de pyy et de glp-1, ou d'un antagoniste correspondant, pour la modification du comportement alimentaire
|
PT1497266E
(pt)
|
2002-03-27 |
2008-09-10 |
Glaxo Group Ltd |
Derivados de quinolina e sua utilização como ligandos 5-ht6
|
JP2005535569A
(ja)
*
|
2002-04-04 |
2005-11-24 |
ノボ・ノルデイスク・エー/エス |
Glp−1アゴニスト及び心臓血管合併症
|
UY27813A1
(es)
|
2002-05-31 |
2003-12-31 |
Smithkline Beecham Corp |
Inhibidores de la peptido-desformilasa
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
MXPA05000130A
(es)
|
2002-06-27 |
2005-02-17 |
Novo Nordisk As |
Derivados de aril-carbonilo como agentes terapeuticos.
|
WO2004052371A2
(fr)
*
|
2002-12-11 |
2004-06-24 |
7Tm Pharma A/S |
Composes de quinoline cycliques utilises avec des troubles lies au recepteur mch
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
MXPA06000795A
(es)
|
2003-07-22 |
2006-08-23 |
Arena Pharm Inc |
Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
|
WO2005023291A2
(fr)
*
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
|
GB0321473D0
(en)
*
|
2003-09-12 |
2003-10-15 |
Glaxo Group Ltd |
Novel compounds
|
RU2381233C2
(ru)
|
2003-09-30 |
2010-02-10 |
Ново Нордиск А/С |
Агонисты рецептора меланокортина
|
EP1694356B1
(fr)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation d'une preference alimentaire au moyen d'agonistes de glp-1
|
KR20070001922A
(ko)
|
2003-12-12 |
2007-01-04 |
와이어쓰 |
심장혈관질환 치료에 유용한 퀴놀린
|
CN102516240A
(zh)
|
2004-01-06 |
2012-06-27 |
诺和诺德公司 |
杂芳基脲及其作为葡糖激酶活化剂的用途
|
WO2005067932A1
(fr)
*
|
2004-01-06 |
2005-07-28 |
Janssen Pharmaceutica, N.V. |
Derives de (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino)-benzamide et composes afferents comme inhibiteurs de la glycogene phosphorylase dans le traitement du diabete et de l'obesite
|
US7501416B2
(en)
|
2004-02-06 |
2009-03-10 |
Bristol-Myers Squibb Company |
Quinoxaline compounds and methods of using them
|
WO2005120492A1
(fr)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
|
JP2008504345A
(ja)
*
|
2004-07-02 |
2008-02-14 |
ノボ ノルディスク アクティーゼルスカブ |
コンデンスチオフェン誘導体(condensedthiophenederivatives)およびそれらのサイクリックGLP−1アゴニストとしての使用
|
CN101060856B
(zh)
|
2004-11-22 |
2011-01-19 |
诺和诺德公司 |
可溶、稳定的含胰岛素制剂
|
EP1824835A1
(fr)
|
2004-12-03 |
2007-08-29 |
Novo Nordisk A/S |
Composes heteroaromatiques activants de glukokinase
|
CN101141964B
(zh)
|
2005-01-10 |
2013-06-05 |
科尔泰多投资公司 |
治疗糖尿病、代谢综合症和其它病症的组合物及方法
|
ES2428510T3
(es)
|
2005-02-02 |
2013-11-08 |
Novo Nordisk A/S |
Derivados de insulina
|
WO2006082205A1
(fr)
|
2005-02-02 |
2006-08-10 |
Novo Nordisk A/S |
Dérivés d'insuline
|
ES2375929T3
(es)
|
2005-07-04 |
2012-03-07 |
High Point Pharmaceuticals, Llc |
Antagonistas del receptor histamina h3.
|
CA2615938C
(fr)
|
2005-07-14 |
2014-04-29 |
Novo-Nordisk A/S |
Activateurs de l'uree glucokinase
|
EP1910317B1
(fr)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
Composés joints en position 1-amino
|
CA2628241C
(fr)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
|
NZ570524A
(en)
|
2006-03-28 |
2011-08-26 |
High Point Pharmaceuticals Llc |
Benzothiazoles having histamine H3 receptor activity
|
ATE538116T1
(de)
|
2006-05-29 |
2012-01-15 |
High Point Pharmaceuticals Llc |
3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
|
EP2076265A4
(fr)
|
2006-10-02 |
2010-09-22 |
Cortendo Invest Ab |
Énantiomère de cétoconazole chez les êtres humains
|
EP2086951B1
(fr)
|
2006-11-15 |
2011-12-21 |
High Point Pharmaceuticals, LLC |
Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
|
CA2669915C
(fr)
|
2006-11-17 |
2012-02-07 |
Pfizer Inc. |
Composes bicyclocarboxyamides substitues
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
AU2008205229B2
(en)
|
2007-01-05 |
2014-03-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
|
WO2008084044A1
(fr)
|
2007-01-11 |
2008-07-17 |
Novo Nordisk A/S |
Activateurs de l'urée glucokinase
|
KR20150116465A
(ko)
|
2007-02-15 |
2015-10-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
TWI366565B
(en)
|
2007-06-06 |
2012-06-21 |
Otsuka Pharma Co Ltd |
Quinolone compound and pharmaceutical composition
|
WO2008154484A1
(fr)
|
2007-06-08 |
2008-12-18 |
Mannkind Corporation |
Inhibiteurs d'ire-1a
|
CA2702289A1
(fr)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
|
CA2707861A1
(fr)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Antagonistes du glucagon
|
EP2508177A1
(fr)
|
2007-12-12 |
2012-10-10 |
Glaxo Group Limited |
Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
WO2009123714A2
(fr)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Procédés de préparation de dérivés de pyrazole utiles comme modulateurs du récepteur de la sérotonine 5-ht<sb>2a</sb>
|
EP2110374A1
(fr)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
|
EP2952202B1
(fr)
|
2008-06-17 |
2017-10-18 |
Indiana University Research and Technology Corporation |
Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
AU2009308232B2
(en)
|
2008-10-23 |
2016-02-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US8513282B2
(en)
|
2008-10-23 |
2013-08-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2010062321A1
(fr)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
|
US8673908B2
(en)
|
2008-11-10 |
2014-03-18 |
Kyowa Hakko Kirin Co., Ltd. |
Kynurenine production inhibitor
|
EP2358200A4
(fr)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
Amines bicycliques substituées pour le traitement du diabète
|
TWI472525B
(zh)
|
2008-12-05 |
2015-02-11 |
Otsuka Pharma Co Ltd |
喹啉酮化合物及藥學組成物
|
AR074811A1
(es)
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
EP2379076B1
(fr)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
|
TWI504395B
(zh)
|
2009-03-10 |
2015-10-21 |
|
Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
|
TW201038565A
(en)
|
2009-03-12 |
2010-11-01 |
Gruenenthal Gmbh |
Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
|
TWI475020B
(zh)
|
2009-03-12 |
2015-03-01 |
|
The substituted nicotine amide as a KCNQ2 / 3 modifier
|
WO2010114824A1
(fr)
|
2009-03-30 |
2010-10-07 |
Transtech Pharma Inc |
Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation
|
KR20120087875A
(ko)
|
2009-06-16 |
2012-08-07 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체-활성 글루카곤 화합물
|
WO2011011506A1
(fr)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
|
CA2768577A1
(fr)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
|
EP2491054A2
(fr)
|
2009-10-22 |
2012-08-29 |
Cadila Healthcare Limited |
Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
|
US8765728B2
(en)
|
2009-11-16 |
2014-07-01 |
Mellitech |
[1,5]-diazocin derivatives
|
EP2512503A4
(fr)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
Co-agonistes du récepteur du glucagon/glp-i
|
JP5540454B2
(ja)
|
2009-12-30 |
2014-07-02 |
シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド |
ジペプチジルペプチダーゼ阻害剤
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
EP2539364A1
(fr)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides de traitement de l'obésité
|
US20130143798A1
(en)
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
EP2555791B1
(fr)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
TWI535442B
(zh)
|
2010-05-10 |
2016-06-01 |
Kyowa Hakko Kirin Co Ltd |
A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
|
CA2797089A1
(fr)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Peptides de la superfamille du glucagon manifestant une activite de recepteur couple a une proteine g
|
CA2797095A1
(fr)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
|
CN103038229B
(zh)
*
|
2010-05-26 |
2016-05-11 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
WO2011163012A2
(fr)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Promédicaments peptidiques à base d'amides de la superfamille du glucagon
|
WO2012025236A1
(fr)
|
2010-08-27 |
2012-03-01 |
Grünenthal GmbH |
2-oxyquinoléine-3-carboxamides substitués comme modulateurs de kcnq2/3
|
AU2011295406B2
(en)
|
2010-08-27 |
2015-08-06 |
Grunenthal Gmbh |
Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
|
AU2011295408B2
(en)
|
2010-08-27 |
2015-05-14 |
Grünenthal GmbH |
Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators
|
EP2611780A1
(fr)
|
2010-09-01 |
2013-07-10 |
Grünenthal GmbH |
1-oxo-dihydroisoquinoline-3-carboxamides substitués en tant que modulateurs des kcnq2/3
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
CN103596583B
(zh)
|
2011-03-28 |
2016-07-27 |
诺沃—诺迪斯克有限公司 |
新型胰高血糖素类似物
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
CA2849673A1
(fr)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Nouveaux analogues du glucagon
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
EP2781517B1
(fr)
|
2011-11-09 |
2017-10-11 |
Kyowa Hakko Kirin Co., Ltd. |
Composé hétérocyclique contenant de l'azote
|
RU2014117678A
(ru)
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
KR20140145624A
(ko)
|
2012-04-16 |
2014-12-23 |
카네크 파마 인코포레이티드 |
Ptp-1b 억제제에 대한 전구체로서의 융합된 방향족 포스포네이트 유도체
|
NZ700928A
(en)
|
2012-04-24 |
2017-06-30 |
Vertex Pharma |
Dna-pk inhibitors
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
EP2864351B1
(fr)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Analogues du glucagon présentant une activité sur le récepteur du gip
|
US20150246117A1
(en)
|
2012-09-24 |
2015-09-03 |
Ulf Eriksson |
Treatment of type 2 diabetes and related conditions
|
US9867869B2
(en)
|
2012-12-12 |
2018-01-16 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
AU2014214326B2
(en)
|
2013-02-07 |
2018-07-05 |
Prexton Therapeutics Sa |
Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4
|
JP6669499B2
(ja)
|
2013-02-15 |
2020-03-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US9353123B2
(en)
|
2013-02-20 |
2016-05-31 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
KR102216284B1
(ko)
|
2013-03-12 |
2021-02-18 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
KR20160021758A
(ko)
|
2013-04-18 |
2016-02-26 |
노보 노르디스크 에이/에스 |
의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
HUE041877T2
(hu)
|
2013-10-17 |
2019-06-28 |
Vertex Pharma |
(S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként
|
CN106061261B
(zh)
|
2013-11-01 |
2018-04-24 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
LT3122359T
(lt)
|
2014-03-26 |
2021-03-25 |
Astex Therapeutics Ltd. |
Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai
|
SI3122358T1
(sl)
|
2014-03-26 |
2021-04-30 |
Astex Therapeutics Ltd. |
Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
|
RU2696588C2
(ru)
|
2014-04-17 |
2019-08-05 |
Мерк Шарп И Доум Корп. |
Комплекс танната ситаглиптина
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
DE102014112747A1
(de)
|
2014-09-04 |
2016-03-10 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
EP4119141A1
(fr)
|
2015-06-12 |
2023-01-18 |
Axovant Sciences GmbH |
Nelotanserin pour la prophylaxie et le traitement d'un trouble du comportement en sommeil paradoxal
|
CA2992518A1
(fr)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Gmbh |
Derives d'arylheretoaryl uree en tant que modulateurs du recepteur serotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associees a une maladie neurodegenerative
|
EP3353177B1
(fr)
|
2015-09-23 |
2020-06-03 |
Janssen Pharmaceutica NV |
Hétérocycliques tricycliques pour la traitement de cancer
|
RU2747644C2
(ru)
|
2015-09-23 |
2021-05-11 |
Янссен Фармацевтика Нв |
Бигетероарил-замещенные 1,4-бензодиазепины и пути их применения для лечения рака
|
AU2017324716B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EP3509421A4
(fr)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
Formes cristallines de composés thérapeutiques et leurs utilisations
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
RU2758669C2
(ru)
|
2016-09-27 |
2021-11-01 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
|
JP2020514365A
(ja)
|
2017-03-15 |
2020-05-21 |
ノヴォ ノルディスク アー/エス |
メラノコルチン4受容体に結合可能な二環式化合物
|
WO2019219714A1
(fr)
|
2018-05-15 |
2019-11-21 |
Novo Nordisk A/S |
Composés capables de se lier au récepteur de la mélanocortine 4
|
WO2020053414A1
(fr)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
|
EP3863634A1
(fr)
|
2018-10-12 |
2021-08-18 |
Strongbridge Dublin Limited |
Lévokétoconazole pour le traitement de l'hyperplasie surrénale congénitale et de l'aldostéronisme primaire
|